CD8A and hepatocellular carcinoma: PROZ is correlated with sorafenib resistance and the number of CD8-positive T infiltrates that represent effective immunotherapy, providing a new potential therapeutic target to improve the efficacy of targeted immune combination therapy for advanced HCC.